These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 17594180)

  • 1. Baculovirus-expressed influenza vaccine. A novel technology for safe and expeditious vaccine production for human use.
    Safdar A; Cox MM
    Expert Opin Investig Drugs; 2007 Jul; 16(7):927-34. PubMed ID: 17594180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A fast track influenza virus vaccine produced in insect cells.
    Cox MM; Hashimoto Y
    J Invertebr Pathol; 2011 Jul; 107 Suppl():S31-41. PubMed ID: 21784229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress on baculovirus-derived influenza vaccines.
    Cox MM
    Curr Opin Mol Ther; 2008 Feb; 10(1):56-61. PubMed ID: 18228182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine.
    Johansson BE
    Vaccine; 1999 Apr; 17(15-16):2073-80. PubMed ID: 10217609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system.
    Brett IC; Johansson BE
    Virology; 2005 Sep; 339(2):273-80. PubMed ID: 15996702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults.
    Treanor JJ; Schiff GM; Couch RB; Cate TR; Brady RC; Hay CM; Wolff M; She D; Cox MM
    J Infect Dis; 2006 May; 193(9):1223-8. PubMed ID: 16586358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a novel recombinant influenza vaccine in insect cells.
    McPherson CE
    Biologicals; 2008 Nov; 36(6):350-3. PubMed ID: 18804387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FluBlok, a next generation influenza vaccine manufactured in insect cells.
    Cox MM; Hollister JR
    Biologicals; 2009 Jun; 37(3):182-9. PubMed ID: 19297194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stable emulsion (SE) alone is an effective adjuvant for a recombinant, baculovirus-expressed H5 influenza vaccine in healthy adults: A Phase 2 trial.
    Treanor JJ; Chu L; Essink B; Muse D; El Sahly HM; Izikson R; Goldenthal KL; Patriarca P; Dunkle LM
    Vaccine; 2017 Feb; 35(6):923-928. PubMed ID: 28089141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.
    King JC; Cox MM; Reisinger K; Hedrick J; Graham I; Patriarca P
    Vaccine; 2009 Nov; 27(47):6589-94. PubMed ID: 19716456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.
    Smith GE; Flyer DC; Raghunandan R; Liu Y; Wei Z; Wu Y; Kpamegan E; Courbron D; Fries LF; Glenn GM
    Vaccine; 2013 Sep; 31(40):4305-13. PubMed ID: 23891795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
    Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
    Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.
    Ryder AB; Buonocore L; Vogel L; Nachbagauer R; Krammer F; Rose JK
    J Virol; 2015 Mar; 89(5):2820-30. PubMed ID: 25540378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influenza viral neuraminidase: the forgotten antigen.
    Johansson BE; Cox MM
    Expert Rev Vaccines; 2011 Dec; 10(12):1683-95. PubMed ID: 22085172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influenza vaccines: the effect of vaccine dose on antibody response in primed populations during the ongoing interpandemic period. A review of the literature.
    Palache AM; Beyer WE; Lüchters G; Völker R; Sprenger MJ; Masurel N
    Vaccine; 1993; 11(9):892-908. PubMed ID: 8212834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1).
    Matassov D; Cupo A; Galarza JM
    Viral Immunol; 2007 Sep; 20(3):441-52. PubMed ID: 17931114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baculovirus-produced influenza virus-like particles in mammalian cells protect mice from lethal influenza challenge.
    Tang XC; Lu HR; Ross TM
    Viral Immunol; 2011 Aug; 24(4):311-9. PubMed ID: 21830902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection.
    Monto AS; Petrie JG; Cross RT; Johnson E; Liu M; Zhong W; Levine M; Katz JM; Ohmit SE
    J Infect Dis; 2015 Oct; 212(8):1191-9. PubMed ID: 25858957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response.
    Johansson BE; Matthews JT; Kilbourne ED
    Vaccine; 1998; 16(9-10):1009-15. PubMed ID: 9682352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.